Human Metabolome Technologies (TSE:6090) Current Deferred Revenue: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6090 Human Metabolome Technologies Inc TSE:6090
62 GF Score
Price 円620.00
GF Value 円694.37
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Human Metabolome Technologies Current Deferred Revenue?

Human Metabolome Technologies TSE:6090 -0.96% 62 Current Deferred Revenue is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円694.37 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Human Metabolome Technologies's current deferred revenue for the quarter that ended in Mar. 2026 was 円0 Mil.

Human Metabolome Technologies Current Deferred Revenue Related Terms

Human Metabolome Technologies Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Current Deferred Revenue Chart

Human Metabolome Technologies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Human Metabolome Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:6090
62GF Score
Human Metabolome Technologies Inc TSE:6090
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of 円0 Mil mean?
Human Metabolome Technologies (TSE:6090) has a Current Deferred Revenue of 円0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Human Metabolome Technologies and its competitors.
Is Human Metabolome Technologies' Current Deferred Revenue too high?
Human Metabolome Technologies' current Current Deferred Revenue is 円0 Mil. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Current Deferred Revenue compare to TMO and DHR?
Human Metabolome Technologies' Current Deferred Revenue of 円0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Current Deferred Revenue is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円694.37, compared to a current price of 円620.00 — trading 10.7% below its estimated fair value. The current Current Deferred Revenue is 円0 Mil. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Current Deferred Revenue is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued. The current stock price of 円620.00 is trading 10.7% below its estimated GF Value™ of 円694.37. GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.

Key valuation signals for TSE:6090:

  • Current Deferred Revenue: 円0 Mil
  • GF Value™: 円694.37 vs. price of 円620.00 (10.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
62GF Score

Get the complete analysis for TSE:6090

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円620.00
Price
円694.37
GF Value